The EverCare team has raised 1.5 MDKK to support the de-risking of a commercial concept based on a technology platform with broad potential. The budget will support Research and Development work to translate the concept into a minimum viable product.
The TresActio team has been accepted to the Novo Nordisk Bioinnovation Institutes Business Accelerator program. Focusing on commercial development of IP generated at Siemens, the team has now raised close to 1MDKK. Congratulations to the entire team on acceptance to the highly competitive program.